CITÓMICA
Hospital Ramón y Cajal
Madrid, EspañaHospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (45)
2024
-
Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723
2023
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
2021
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
2020
-
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2019
-
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials
European Journal of Haematology, Vol. 102, Núm. 1, pp. 79-86
2018
-
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 7, pp. 1634-1643
2016
2015
-
Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality
Blood, Vol. 126, Núm. 7, pp. 858-862
2012
-
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors
EMBO Journal, Vol. 31, Núm. 18, pp. 3704-3717
-
Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 67, Núm. 6, pp. 813-821
2011
-
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Journal of Clinical Oncology, Vol. 29, Núm. 12, pp. 1627-1633
-
Dermoscopic features of skin lesions in patients with mastocytosis
Archives of Dermatology, Vol. 147, Núm. 8, pp. 932-940
-
Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis
Cytometry Part B - Clinical Cytometry, Vol. 80 B, Núm. 3, pp. 167-175
2010
-
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms
Journal of Allergy and Clinical Immunology, Vol. 125, Núm. 6
-
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
Journal of Allergy and Clinical Immunology, Vol. 125, Núm. 3
2009
-
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
Journal of Allergy and Clinical Immunology, Vol. 124, Núm. 3, pp. 514-521
2008
-
CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking
International Journal of Immunopathology and Pharmacology, Vol. 21, Núm. 4, pp. 797-806